MediGene Buys Rheumatoid Arthritis Drug With Avidex Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
RhuDex is a potential blockbuster entering Phase IIa clinical trials, the German biotech says.
You may also be interested in...
Patient Death Halts Phase I Trial For MediGene RA Candidate
Talked up as a potential blockbuster, RhuDex produced positive Phase IIa findings a month earlier.
Patient Death Halts Phase I Trial For MediGene RA Candidate
Talked up as a potential blockbuster, RhuDex produced positive Phase IIa findings a month earlier.
Polyphenon E User Fee Date Extended To October
Bradley/MediGene AG's Polyphenon E ointment has a new user fee date of Oct. 31, 2006, Bradley said June 30